{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:34Z","timestamp":1777984354330,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04278-7","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:16:22Z","timestamp":1773407782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sentinel lymph node status and oncological outcomes of high-risk and low-risk cutaneous primary melanoma"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-4845","authenticated-orcid":false,"given":"Hesham S.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Fadel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olympia","family":"Hadjicosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieran","family":"Power","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myles J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"4278_CR1","doi-asserted-by":"crossref","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiol Melanoma Med Sci (Basel). 2021;9(4):63.","DOI":"10.3390\/medsci9040063"},{"issue":"2","key":"4278_CR2","first-page":"128","volume":"159","author":"LA Nurla","year":"2024","unstructured":"Nurla LA, Forsea AM. Melanoma epidemiology in Europe: what is new. Ital J Dermatol Venerol. 2024;159(2):128\u201334.","journal-title":"Ital J Dermatol Venerol"},{"issue":"11","key":"4278_CR3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.2010.33.1884","volume":"29","author":"ME Valsecchi","year":"2011","unstructured":"Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29(11):1479\u201387.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4278_CR4","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1245\/s10434-014-4349-3","volume":"22","author":"MJ Speijers","year":"2015","unstructured":"Speijers MJ, Bastiaannet E, Sloot S, Suurmeijer AJ, Hoekstra HJ. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015;22(9):2978\u201387.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4278_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5694\/mja15.00148","volume":"203","author":"SL Smithson","year":"2015","unstructured":"Smithson SL, Pan Y, Mar V. Differing trends in thickness and survival between nodular and non-nodular primary cutaneous melanoma in Victoria, Australia. Med J Aust. 2015;203(1):20.","journal-title":"Med J Aust"},{"issue":"10","key":"4278_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.bjps.2011.05.001","volume":"64","author":"MG Rughani","year":"2011","unstructured":"Rughani MG, Swan MC, Adams TS, Middleton MR, Ramcharan RN, Pay A, et al. Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience. J Plast Reconstr Aesthet Surg. 2011;64(10):1284\u201390.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"1","key":"4278_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bjps.2019.06.020","volume":"73","author":"H Peach","year":"2020","unstructured":"Peach H, Board R, Cook M, Corrie P, Ellis S, Geh J, et al. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. J Plast Reconstr Aesthet Surg. 2020;73(1):36\u201342.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"13","key":"4278_CR8","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1245\/s10434-011-1826-9","volume":"18","author":"RL White Jr","year":"2011","unstructured":"White RL Jr., Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011;18(13):3593\u2013600.","journal-title":"Ann Surg Oncol"},{"key":"4278_CR9","doi-asserted-by":"crossref","unstructured":"Jeremic J, Radenovic K, Jurisic M, Sudecki B, Marinkovic M, Mihaljevic J et al. Primary Melanoma Histopathologic Predictors of Sentinel Lymph Node Positivity: A Proposed Scoring System for Risk Assessment and Patient Selection in a Clinical Setting. Med (Kaunas). 2023;59(11):1921.","DOI":"10.3390\/medicina59111921"},{"issue":"3","key":"4278_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","volume":"242","author":"DL Morton","year":"2005","unstructured":"Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302\u201311. discussion 11\u2009\u2013\u20093.","journal-title":"Ann Surg"},{"issue":"23","key":"4278_CR11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med"},{"issue":"32","key":"4278_CR12","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.18.02306","volume":"37","author":"U Leiter","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019;37(32):3000\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4278_CR13","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","volume":"23","author":"GV Long","year":"2022","unstructured":"Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23(11):1378\u201388.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4278_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP Jr., Yost KJ, Hyngstrom JR, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813\u201323.","journal-title":"N Engl J Med"},{"key":"4278_CR15","unstructured":"(1) MIoA. Sentinel Node Metastasis Prediction Tool 2024 [Available from: https:\/\/www.melanomarisk.org.au\/SNLLand. Accesses January 16, 2026."},{"issue":"4","key":"4278_CR16","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1245\/s10434-023-14862-w","volume":"31","author":"S Maddineni","year":"2024","unstructured":"Maddineni S, Dizon MP, Muralidharan V, Young LA, Sunwoo JB, Baik FM, et al. Validation of the Melanoma Institute of Australia\u2019s Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma. Ann Surg Oncol. 2024;31(4):2737\u201346.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"4278_CR17","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;29(11):2835\u201343.","journal-title":"Nat Med"},{"issue":"5","key":"4278_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/bjd\/ljaf016","volume":"192","author":"MJ Smith","year":"2025","unstructured":"Smith MJ, Peach H, Keohane S, Lear J, Jamieson LA, Mohamed HS, et al. Melanoma: assessment and management summary of the 2022 update of the National Institute for Health and Care Excellence guidelines. Br J Dermatol. 2025;192(5):807\u201317.","journal-title":"Br J Dermatol"},{"issue":"6","key":"4278_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","volume":"18","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (2): explanation and elaboration. Epidemiology. 2007;18(6):805\u201335.","journal-title":"Epidemiology"},{"key":"4278_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","volume":"119","author":"T Kanaki","year":"2019","unstructured":"Kanaki T, Stang A, Gutzmer R, Zimmer L, Chorti E, Sucker A, et al. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. Eur J Cancer. 2019;119:18\u201329.","journal-title":"Eur J Cancer"},{"key":"4278_CR21","unstructured":"UK Mf-. Melanoma survival rates [Available from: https:\/\/melanomafocus.org\/melanoma-patient-treatment-guide\/living-with-melanoma\/melanoma-survival-rates\/. Accesses January 16, 2026."},{"issue":"13","key":"4278_CR22","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1245\/s10434-023-14050-w","volume":"30","author":"CJ Holmberg","year":"2023","unstructured":"Holmberg CJ, Mikiver R, Isaksson K, Ingvar C, Moncrieff M, Nielsen K, et al. Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (>\u20094\u00a0mm). Ann Surg Oncol. 2023;30(13):8026\u201333.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4278_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/000313480407000114","volume":"70","author":"IA Jacobs","year":"2004","unstructured":"Jacobs IA, Chang CK, Salti GI. Role of sentinel lymph node biopsy in patients with thick (>\u20094\u00a0mm) primary melanoma. Am Surg. 2004;70(1):59\u201362.","journal-title":"Am Surg"},{"issue":"2","key":"4278_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s10434-000-0160-4","volume":"7","author":"JE Gershenwald","year":"2000","unstructured":"Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (>\u2009or =\u20094\u00a0mm) primary melanoma. Ann Surg Oncol. 2000;7(2):160\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"4278_CR25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1200\/JCO.2010.31.5812","volume":"29","author":"JF Thompson","year":"2011","unstructured":"Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29(16):2199\u2013205.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4278_CR26","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/cncr.11196","volume":"97","author":"MF Azzola","year":"2003","unstructured":"Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97(6):1488\u201398.","journal-title":"Cancer"},{"issue":"6","key":"4278_CR27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2019.0440","volume":"155","author":"LA von Schuckmann","year":"2019","unstructured":"von Schuckmann LA, Hughes MCB, Ghiasvand R, Malt M, van der Pols JC, Beesley VL, et al. Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor. JAMA Dermatol. 2019;155(6):688\u201393.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"4278_CR28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1245\/s10434-015-4894-4","volume":"23","author":"DE Gyorki","year":"2016","unstructured":"Gyorki DE, Sanelli A, Herschtal A, Lazarakis S, McArthur GA, Speakman D, et al. Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool. Ann Surg Oncol. 2016;23(2):579\u201384.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4278_CR29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1245\/s10434-020-08706-0","volume":"28","author":"D Han","year":"2021","unstructured":"Han D, Han G, Duque MT, Morrison S, Leong SP, Kashani-Sabet M, et al. Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. Ann Surg Oncol. 2021;28(2):1007\u201316.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4278_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(24)00076-7","volume":"25","author":"RC Stassen","year":"2024","unstructured":"Stassen RC, Maas C, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, et al. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. Lancet Oncol. 2024;25(4):509\u201317.","journal-title":"Lancet Oncol"},{"issue":"22","key":"4278_CR31","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1200\/JCO.19.03034","volume":"38","author":"C Garbe","year":"2020","unstructured":"Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, et al. Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. J Clin Oncol. 2020;38(22):2543\u201351.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4278_CR32","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1245\/s10434-019-07448-y","volume":"26","author":"K Isaksson","year":"2019","unstructured":"Isaksson K, Katsarelias D, Mikiver R, Carneiro A, Ny L, Olofsson Bagge R. A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. Ann Surg Oncol. 2019;26(9):2839\u201345.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"4278_CR33","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1245\/s10434-009-0665-4","volume":"16","author":"AA Ghaferi","year":"2009","unstructured":"Ghaferi AA, Wong SL, Johnson TM, Lowe L, Chang AE, Cimmino VM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol. 2009;16(11):2978\u201384.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4278_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1245\/s10434-008-0187-5","volume":"16","author":"C Ariyan","year":"2009","unstructured":"Ariyan C, Brady MS, Gonen M, Busam K, Coit D. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16(1):186\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"4278_CR35","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1245\/s10434-010-1208-8","volume":"17","author":"RE Brown","year":"2010","unstructured":"Brown RE, Ross MI, Edwards MJ, Noyes RD, Reintgen DS, Hagendoorn LJ, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2010;17(12):3330\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"4278_CR36","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1245\/s10434-009-0530-5","volume":"16","author":"JW Jakub","year":"2009","unstructured":"Jakub JW, Huebner M, Shivers S, Nobo C, Puleo C, Harmsen WS. The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node. Ann Surg Oncol. 2009;16(8):2245\u201351.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4278_CR37","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1245\/s10434-023-14724-5","volume":"31","author":"A Dedeilia","year":"2024","unstructured":"Dedeilia A, Lwin T, Li S, Tarantino G, Tunsiricharoengul S, Lawless A, et al. Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma. Ann Surg Oncol. 2024;31(4):2713\u201326.","journal-title":"Ann Surg Oncol"},{"issue":"10336","key":"4278_CR38","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718\u201329.","journal-title":"Lancet"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04278-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04278-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04278-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:25:35Z","timestamp":1776810335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04278-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4278"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04278-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8321644\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patient information, data collection and analysis were performed After Institutional Review Board approval and in compliance with the Royal Marsden Hospital research ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}